Disease-modifying therapies (DMTs) are treatments designed to slow, halt, or partially reverse the underlying process driving a disease, rather than just relieving symptoms. Where a painkiller masks joint pain or a dopamine-replacement drug temporarily restores movement, a disease-modifying therapy targets the biological machinery that causes damage in the first place. They are most established in multiple sclerosis and rheumatoid arthritis, with newer approvals now reaching Alzheimer’s disease.
How DMTs Differ From Symptom Relief
Most medications people take for chronic conditions are symptomatic. They correct a chemical imbalance or block a pain signal without changing the trajectory of the disease itself. In Alzheimer’s, for example, older drugs work by boosting a brain chemical that declines as neurons die. They can modestly improve memory for a time, but the disease keeps progressing underneath. In Parkinson’s, standard treatment replaces dopamine the brain can no longer produce. Patients feel better, yet the neurons continue to degenerate.
A disease-modifying therapy, by contrast, intervenes at the level of what’s actually destroying tissue. It might calm an overactive immune system that’s attacking the body’s own cells, clear toxic protein buildup in the brain, or block the inflammatory signals that erode joint cartilage. The goal isn’t to make you feel better today (though it often does over time). The goal is to change where the disease will be in five or ten years.
What DMTs Do Inside the Body
Most disease-modifying therapies work by recalibrating the immune system. In autoimmune conditions like MS and rheumatoid arthritis, the immune system mistakenly attacks healthy tissue. DMTs interrupt this process through several strategies: blocking the inflammatory signaling molecules that recruit immune cells to attack, preventing immune cells from reaching their targets, depleting specific populations of immune cells responsible for damage, or trapping immune cells in lymph nodes so they never enter the bloodstream.
In Alzheimer’s disease, the approach is different. Rather than targeting the immune system’s behavior, newer therapies are antibodies engineered to bind to amyloid beta plaques, the sticky protein clumps that accumulate between brain cells. By flagging these plaques for removal, the treatments address one of the defining features of Alzheimer’s pathology.
Conditions With Approved DMTs
Multiple Sclerosis
MS has the most mature landscape of disease-modifying options. At least 18 DMTs have been approved for relapsing forms of the disease, and one is approved for the primary progressive form. These span several drug classes with different mechanisms. Interferons, available since the 1990s, reduce inflammation-promoting signals and boost anti-inflammatory ones. Sphingosine 1-phosphate receptor modulators (taken as pills) work by trapping certain immune cells inside lymph nodes, keeping them out of circulation where they would attack nerve insulation. Monoclonal antibodies, given by infusion, can deplete B cells, block immune cells from crossing into the brain, or redirect immune signaling away from harmful pathways.
The practical differences among these therapies are significant. Efficacy, measured by how much they reduce the annual rate of relapses compared to placebo, ranges from about 29% to 68% depending on the drug class. Higher-efficacy options tend to carry more potential side effects, which is why treatment strategy has been a long-running debate in the field.
Rheumatoid Arthritis
In rheumatoid arthritis, disease-modifying antirheumatic drugs (DMARDs) fall into three categories. Conventional synthetic DMARDs are older, broadly acting oral medications that dampen the immune system as a whole. Biologic DMARDs are protein-based drugs, given by injection or infusion, that target specific inflammatory molecules or immune cells outside of cells. Targeted synthetic DMARDs are newer oral pills that block signaling pathways inside immune cells, preventing them from activating. Starting a DMARD early, ideally within months of diagnosis, is a core principle in rheumatology because joint damage that occurs before treatment begins is largely irreversible.
Alzheimer’s Disease
Alzheimer’s entered the disease-modification era more recently. In July 2024, the FDA approved donanemab, an antibody that targets amyloid plaques in the brain, for adults with mild cognitive impairment or mild dementia due to Alzheimer’s. Patients must have confirmed amyloid buildup before starting treatment. This followed the earlier approval of lecanemab, another amyloid-targeting antibody. These drugs do not restore lost cognitive function, but clinical trials showed they slowed the rate of decline. No disease-modifying therapies exist yet for Parkinson’s disease, where patients still rely on decades-old symptomatic treatments.
How DMTs Are Taken
The practical experience of being on a DMT varies widely. Some are daily pills you take at home. Others are self-administered injections given under the skin every week, every two weeks, or once a month. The highest-efficacy options in MS are often intravenous infusions, administered at a clinic anywhere from every six months to once a year. Alzheimer’s antibody therapies also require regular infusions at a treatment center, typically every two to four weeks, with periodic brain scans to monitor for side effects.
This variety in administration matters because it affects daily life, work schedules, and willingness to stick with treatment. For many people, the choice between therapies involves weighing how effective a drug is against how convenient and tolerable it is to take.
Starting Early vs. Escalating Gradually
One of the most important decisions in disease-modifying treatment is when to start and how aggressively. In MS, two competing strategies have shaped clinical practice. The escalation approach begins with a lower-risk, moderate-efficacy drug and switches to something stronger only if the disease breaks through. This has been the dominant model for years. The early intensive therapy approach starts with a high-efficacy drug from the outset, aiming to maximize benefit during a critical early window.
Evidence increasingly favors acting early. Observational studies suggest that early intensive therapy provides greater long-term benefit in reducing disability and lowering the risk of transitioning to a progressive form of the disease, at least over 5 to 10 years of follow-up. Research points to a window of opportunity, roughly the first five years after diagnosis, during which aggressive treatment has the greatest impact. After that window, the effect on preventing disability accumulation appears to diminish, possibly because aging-related changes in the immune system reduce the treatment’s leverage.
Moderate-efficacy drugs still reduce relapses effectively over time, but their ability to prevent long-term disability accumulation may plateau after four to five years. This doesn’t make them useless, but it does mean the stakes of the initial treatment choice are higher than once thought.
Monitoring While on Treatment
Because DMTs work by altering immune function, they require regular safety monitoring. Before starting most MS therapies, doctors run a panel of blood tests checking immune cell counts, liver and kidney function, and screening for latent infections like tuberculosis and certain viruses. Some drugs require checking for a specific virus (JC virus) that can cause a rare but serious brain infection in immunosuppressed patients.
Ongoing monitoring depends on the specific therapy. Some drugs need blood work monthly for the first six months, then every six months after that. Others need checks only twice a year. A few require almost no routine lab work at all. The monitoring burden is one more factor that shapes treatment decisions, particularly for people who live far from medical centers or have demanding schedules.
Why One Size Doesn’t Fit All
A growing recognition in disease-modifying therapy is that people with the same diagnosis often have different biological drivers underneath. Two people with the same neurodegenerative condition may have distinct molecular subtypes of that disease, meaning the same therapy could work for one and fail for the other. Matching patients to the therapy most likely to benefit them, rather than cycling through options by trial and error, is increasingly seen as essential. This is already influencing Alzheimer’s treatment, where amyloid-targeting drugs only work in patients with confirmed amyloid pathology. The principle is likely to expand as researchers identify more biological subtypes across other conditions.